Last-Resort drug access for severe colitis patients
NCT ID NCT06025227
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This program provides early access to the drug etrasimod for people with severe ulcerative colitis who have tried at least three other treatments without success or cannot use them. The goal is to offer a potential treatment option when no standard therapies are available. Patients must meet strict eligibility criteria to participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.